{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:50:54Z","timestamp":1790722254420,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T00:00:00Z","timestamp":1521417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00535-018-1449-z","type":"journal-article","created":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T14:38:01Z","timestamp":1521470281000},"page":"585-590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":160,"title":["New treatment options for inflammatory bowel diseases"],"prefix":"10.1007","volume":"53","author":[{"given":"Bram","family":"Verstockt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Van Assche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,19]]},"reference":[{"issue":"1","key":"1449_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14712598.2017.1258399","volume":"17","author":"B Verstockt","year":"2017","unstructured":"Verstockt B, Van Assche G, Vermeire S, et al. Biological therapy targeting the IL-23\/IL-17 axis in inflammatory bowel disease. Expert Opin Biol Ther. 2017;17(1):31\u201347.","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"1449_CR2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/14740338.2017.1338273","volume":"16","author":"B Verstockt","year":"2017","unstructured":"Verstockt B, Deleenheer B, Van Assche G, et al. A safety assessment of biological therapies targeting the IL-23\/IL-17 axis in inflammatory bowel diseases. Expert Opin Drug Saf. 2017;16(7):809\u201321.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"1449_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/apt.12639","volume":"39","author":"T Lobaton","year":"2014","unstructured":"Lobaton T, Vermeire S, Van Assche G, et al. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(6):579\u201394.","journal-title":"Aliment Pharmacol Ther"},{"issue":"18","key":"1449_CR4","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","volume":"374","author":"WJ Sandborn","year":"2016","unstructured":"Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374(18):1754\u201362.","journal-title":"N Engl J Med"},{"issue":"18","key":"1449_CR5","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723\u201336.","journal-title":"N Engl J Med"},{"issue":"10066","key":"1449_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","volume":"389","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266\u201375.","journal-title":"Lancet"},{"issue":"7","key":"1449_CR7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/ecco-jcc\/jjx003","volume":"11","author":"LCS Vries De","year":"2017","unstructured":"De Vries LCS, Wildenberg ME, De Jonge WJ, et al. The future of Janus kinase inhibitors in inflammatory bowel disease. J Crohns Colitis. 2017;11(7):885\u201393.","journal-title":"J Crohns Colitis"},{"key":"1449_CR8","doi-asserted-by":"publisher","unstructured":"Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, et al. Long-term efficacy and safety of stem cell therapy (C\u00d7601) for complex perianal fistulas in patients with Crohn\u2019s disease. Gastroenterology. 2017. https:\/\/doi.org\/10.1053\/j.gastro.2017.12.020 .","DOI":"10.1053\/j.gastro.2017.12.020"},{"issue":"4","key":"1449_CR9","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","volume":"135","author":"WJ Sandborn","year":"2008","unstructured":"Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease. Gastroenterology. 2008;135(4):1130\u201341.","journal-title":"Gastroenterology"},{"issue":"16","key":"1449_CR10","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease. N Engl J Med. 2012;367(16):1519\u201328.","journal-title":"N Engl J Med"},{"issue":"20","key":"1449_CR11","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s Disease. N Engl J Med. 2016;375(20):1946\u201360.","journal-title":"N Engl J Med"},{"issue":"9","key":"1449_CR12","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","volume":"151","author":"RE Kalb","year":"2015","unstructured":"Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol. 2015;151(9):961\u20139.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1449_CR13","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.cgh.2017.03.032","volume":"15","author":"R Battat","year":"2017","unstructured":"Battat R, Kopylov U, Bessissow T, et al. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2017;15(9):1427\u201334 (e2).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1449_CR14","doi-asserted-by":"publisher","unstructured":"Adedokun O, Xu Z, Gasink et al. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn\u2019s disease. Gastroenterology. 2018. https:\/\/doi.org\/10.1053\/j.gastro.2018.01.043 .","DOI":"10.1053\/j.gastro.2018.01.043"},{"issue":"1","key":"1449_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","volume":"153","author":"BE Sands","year":"2017","unstructured":"Sands BE, Chen J, Feagan BG, et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn\u2019s Disease: a phase 2a study. Gastroenterology. 2017;153(1):77\u201386 (e6).","journal-title":"Gastroenterology"},{"issue":"10080","key":"1449_CR16","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","volume":"389","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, Sandborn WJ, D\u2019Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699\u2013709.","journal-title":"Lancet"},{"issue":"16","key":"1449_CR17","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","volume":"376","author":"KA Papp","year":"2017","unstructured":"Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus Ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551\u201360.","journal-title":"N Engl J Med"},{"issue":"4","key":"1449_CR18","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/bjd.13932","volume":"173","author":"K Papp","year":"2015","unstructured":"Papp K, Tha\u00e7i D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1449_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1056\/NEJMoa1501646","volume":"373","author":"KB Gordon","year":"2015","unstructured":"Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136\u201344.","journal-title":"N Engl J Med"},{"issue":"11","key":"1449_CR20","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00228-016-2110-5","volume":"72","author":"Y Zhuang","year":"2016","unstructured":"Zhuang Y, Calderon C, Marciniak SJ, et al. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics\/safety in healthy subjects and patients with moderate-to-severe psoriasis. Eur J Clin Pharmacol. 2016;72(11):1303\u201310.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"1449_CR21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nri2785","volume":"10","author":"S Sakaguchi","year":"2010","unstructured":"Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7):490\u2013500.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"1449_CR22","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1097\/MIB.0000000000000210","volume":"20","author":"AM Globig","year":"2014","unstructured":"Globig AM, Hennecke N, Martin B, et al. Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-gamma+ IL-17+ coproducing CD4+ T cells in active inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(12):2321\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"1449_CR23","doi-asserted-by":"crossref","unstructured":"Targan SR, Feagan GB, Vermeire S, Panaccione R, Melmed GY, Blosch C, Newmark R, Zhang N, et al. A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn\u2019s disease. Gastroenterology. 2012;143(3):e26.","DOI":"10.1053\/j.gastro.2012.07.084"},{"issue":"1","key":"1449_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/gut.52.1.65","volume":"52","author":"S Fujino","year":"2003","unstructured":"Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65\u201370.","journal-title":"Gut"},{"issue":"3","key":"1449_CR25","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","volume":"73","author":"D Thaci","year":"2015","unstructured":"Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1449_CR26","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693\u2013700.","journal-title":"Gut"},{"issue":"9940","key":"1449_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","volume":"384","author":"S Vermeire","year":"2014","unstructured":"Vermeire S, O\u2019Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384(9940):309\u201318.","journal-title":"Lancet"},{"issue":"10090","key":"1449_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0140-6736(17)30930-3","volume":"390","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, Sandborn WJ, Danese S, et al. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10090):135\u201344.","journal-title":"Lancet"},{"issue":"6","key":"1449_CR29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","volume":"66","author":"J Panes","year":"2017","unstructured":"Panes J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66(6):1049\u201359.","journal-title":"Gut"},{"key":"1449_CR30","doi-asserted-by":"crossref","unstructured":"Sandborn W, Feagan B, Panes J, et al. Safety and efficacy of ABT-494 (Upadacitinib), an oral Jak1 inhibitor, as induction therapy in patients with Crohn\u2019s disease: results from celest. Digestive Disease Week 2017; Chicago2017.","DOI":"10.1016\/S0016-5085(17)34357-3"},{"issue":"4","key":"1449_CR31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/ecco-jcc\/jjv203","volume":"10","author":"S Vermeire","year":"2016","unstructured":"Vermeire S, Joossens M, Verbeke K, et al. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis. 2016;10(4):387\u201394.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"1449_CR32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","volume":"149","author":"P Moayyedi","year":"2015","unstructured":"Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149(1):102\u20139 (e6).","journal-title":"Gastroenterology"},{"issue":"1","key":"1449_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.gastro.2015.03.045","volume":"149","author":"NG Rossen","year":"2015","unstructured":"Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149(1):110\u20138 (e4).","journal-title":"Gastroenterology"},{"issue":"10075","key":"1449_CR34","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","volume":"389","author":"S Paramsothy","year":"2017","unstructured":"Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218\u201328.","journal-title":"Lancet"},{"key":"1449_CR35","doi-asserted-by":"publisher","unstructured":"Costello S, Water O, Bryant R, et al. Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial. Gastroenterology. 2017;152(5):S198\u2013S199. https:\/\/doi.org\/10.1016\/S0016-5085(17)30969-1 .","DOI":"10.1016\/S0016-5085(17)30969-1"},{"issue":"25","key":"1449_CR36","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1056\/NEJMc1504845","volume":"372","author":"G Monteleone","year":"2015","unstructured":"Monteleone G, Pallone F. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn\u2019s disease. N Engl J Med. 2015;372(25):2461.","journal-title":"N Engl J Med"},{"issue":"9","key":"1449_CR37","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/apt.12051","volume":"36","author":"F Zorzi","year":"2012","unstructured":"Zorzi F, Calabrese E, Monteleone I, et al. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn\u2019s disease. Aliment Pharmacol Ther. 2012;36(9):850\u20137.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-018-1449-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-018-1449-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-018-1449-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T03:51:57Z","timestamp":1570938717000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-018-1449-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,19]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["1449"],"URL":"https:\/\/doi.org\/10.1007\/s00535-018-1449-z","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,19]]},"assertion":[{"value":"6 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author must indicate whether or not they have\/had a financial relationship (within the last 3\u00a0years) with any organization that sponsored the research. They should also confirm that they have full control of all primary data and that they agree to allow the journal to review their data if requested.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}